Oncology Institute (NASDAQ:TOI) Trading 11.9% Higher Following Insider Buying Activity

Posted by George Bondi on Jun 8th, 2026

The Oncology Institute, Inc. (NASDAQ:TOI – Get Free Report)’s share price shot up 11.9% during mid-day trading on Monday following insider buying activity. The company traded as high as $5.49 and last traded at $5.4510. 493,754 shares were traded during trading, a decline of 74% from the average session volume of 1,878,680 shares. The stock had previously closed at $4.87.

Specifically, major shareholder Jorey Chernett acquired 12,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were bought at an average price of $4.75 per share, with a total value of $57,000.00. Following the completion of the purchase, the insider directly owned 10,579,858 shares in the company, valued at $50,254,325.50. This trade represents a 0.11% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on TOI shares. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 target price on shares of Oncology Institute in a report on Monday, March 9th. B. Riley Financial raised their price target on Oncology Institute from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research note on Monday, April 20th. Finally, BTIG Research increased their target price on shares of Oncology Institute from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

View Our Latest Stock Report on Oncology Institute

Oncology Institute Stock Up 12.2%

The company has a market cap of $539.86 million, a PE ratio of -14.69 and a beta of 0.37. The firm has a 50 day simple moving average of $3.78 and a 200-day simple moving average of $3.39.

Oncology Institute (NASDAQ:TOI – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. The firm had revenue of $147.44 million during the quarter, compared to the consensus estimate of $142.10 million. As a group, equities analysts anticipate that The Oncology Institute, Inc. will post -0.17 EPS for the current year.

Institutional Investors Weigh In On Oncology Institute

Several institutional investors have recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new position in shares of Oncology Institute during the fourth quarter worth $31,000. Pekin Hardy Strauss Inc. acquired a new stake in shares of Oncology Institute in the 4th quarter worth $36,000. Cetera Investment Advisers grew its stake in Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after buying an additional 4,545 shares during the last quarter. State of Wyoming purchased a new position in Oncology Institute during the 2nd quarter worth $37,000. Finally, R Squared Ltd acquired a new position in Oncology Institute during the 4th quarter valued at about $41,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.

About Oncology Institute

(Get Free Report)

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.